Perpetual Ltd Sells 25,064 Shares of Pfizer Inc. $PFE

Perpetual Ltd lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 18.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,392 shares of the biopharmaceutical company’s stock after selling 25,064 shares during the period. Perpetual Ltd’s holdings in Pfizer were worth $2,838,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the first quarter worth about $27,000. Curio Wealth LLC grew its stake in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the second quarter valued at $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn’t Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Pfizer Stock Up 0.6%

Shares of NYSE:PFE opened at $25.19 on Friday. The firm has a market capitalization of $143.22 billion, a PE ratio of 14.65 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The firm has a fifty day moving average of $25.10 and a 200 day moving average of $24.84.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.